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Abstract The objective of present invesigation was to formulate and evaluate 
a niosomal delivery system of moxifloxacin hydrchloride for the treatment of 
ocular infections. Moxifloxacin-loaded niosomes were prepared by using thin 
film hydration technique and were investigated for surface pH, morphology, 
entrapment, in-vitro release, TeM (transmission electron microscopy), physical 
stability & ocular irritancy test. The release study profile was subjected to 
release kinetics models. all the vesicles were uniform and spherical in size. 
The drug relaese pattern of all formulation follows decreasing order: MN3 > 
MN6 > MN9 > MN5 > MN2 > MN1 > MN8 > MN4 > MN7. The formulation 
MN3 (span 60: cholesterol) molar ratio produce faster release of drug i.e. 
77.98% after 12 hours, concluded less sustained action. The study concluded 
that the moxifloxacin loaded niosomes to be effective in sustaining the drug 
release leading to decreased side effects and increased patient compliance 
Keyword: Moxifoxacin, Niosomes, Film Hydration Technique, sustianed 
release.
1. INTRODUCTION 
eye is the most simply accessible site for topical administration of a 
medication. Drugs are commonly applied to the ocular system for a localized 




drug delivery has been a foremost challenge for researchers because of the 
distinctive anatomy and physiology of eye which contains different barriers 
such as different layers of cornea, sclera and retina in addition to blood retinal 
barriers, lachrymal fluid-eye barrier and also drug loss from the ocular surface. 
The major challenge to the formulator is to outwit these barriers without 
causing any tissue damage (Tangri et al., 2011). The cornea is the anterior 
layer of the eye, comprises of epithelium, stroma and endothelium. However, 
this layer represents a mechanical barrier restraining the delivery of drug 
molecules. Due to their high lipid content, the epithelium and the endothelium 
are considered as an obstruction to the passage of hydrophilic molecules. 
The stroma is characterized by a high water content that makes this layer 
impermeable to lipophilic molecules (achouri et al., 2013). Corneal barrier 
also plays a considerable role in low ocular bioavailability due to which only < 
5% of the applied drugs are able to penetrate though the cornea into the intra-
ocular tissues (Maurice, 1984). Inconvenience in using conventional dosage 
forms are as follows:
Limited permeability which leads to lower absorption.•	
Rapid elimination.•	
Frequent instillation.•	
Lower bioavailability due to low precorneal residence time.•	
Drainage of drugs from nasolacrimal duct (Kumar, 2012; Patel, 2010)•	
The conventional ophthalmic dosage forms suffer from many disadvantages 
including precorneal loss due to tear dynamics, insufficient residence time 
in the conjunctival sac and non-productive absorption. In the formulation of 
ophthalmic dosage forms, great attention is now being devoted to new drug 
delivery systems which can ensure a localised effect over prolonged time 
duration and increase the corneal permeability of poorly permeable drugs. To 
achieve these objectives i.e. to increase the corneal residence time, to obtain 
maximum corneal permeability and sustained drug release, several vesicular 
systems have been investigated (Shell, 1982; Habib, 2010; aggarwal, 2004). 
These all systems have some drawbacks like unable to control the drug 
permeation through cornea; consequently, the drug concentration at the site of 
action might remain inadequate. 
To overcome these problems, vesicular systems have been prepared to 
increase corneal permeation by formulating a lipid complex and enhance the 
percent permeation by a controlling manner. Niosomes are non-ionic surfactant 
vesicles and like liposomes, are bi layered structures, which can entrap both 
hydrophilic as well as lipophilic drugs, either in the aqueous layer or in lipid 










Niosomes in topical ocular delivery are preferred over other vesicular 
systems because they are chemically stable as compared to liposomes due to 
the presence of negative charges, have low toxicity because of their non-ionic 
nature; unlike phospholipid, require no special precautions in handling and 
exhibit better flexibility in their structure (Carafa, 1998). Moreover, non-ionic 
surfactant vesicles (niosomes) may promote drug absorption by preferentially 
modifying the permeability characteristics of the conjunctival and scleral 
membranes.
Moxifloxacin is a fourth generation fluoroquinolone with methoxy 
group in C-8 position and a bulky C-7 side chain (Yoshioka, 1994). Like 
other fluoroquinolones, moxifloxacin (0.5%w/v) eye drops require 1-2 drops 
administered 6 times daily or more in severe conditions.The bactericidal activity 
of moxifloxacin is mediated by the inhibition of DNa gyrase (topoisomerase II) 
and topoisomerase IV, essential enzymes involved in bacterial DNa replication, 
transcription, repair, and recombination (Pestova, 2000). Moxifloxacin is more 
effective than ciprofloxacin or levofloxacin in experimental keratitis in rabbits 
(Dajcs, 2004). Penetration of moxifloxacin into the inflamed ocular tissue of 
rabbits has been found to be better than ciprofloxacin, lomefloxacin, ofloxacin, 
or levofloxacin (Yagci, 2007).
The niosomal drug delivery has been known to prolong the corneal residence 
time and maintain drug concentration in vitreous humor and aqueous humor 
by penetrating the corneal barrier i.e. in sustained manner. Recent vesicular 
systems have shown significant drug level in aqueous humor. Niosomal 
drug delivery in ophthalmic medication also showed improved transcorneal 
permeation of many drugs over conventional ophthalmic solutions (Hardman, 
2001; Kaur, 2010; abdelkader, 2011).
2. MATERIALS AND METHODS 
2.1 Materials 
Moxifloxacin hydrochloride was received from Ind-Swift Laboratories 
Limited, Derabassi, Punjab, India as a gift sample. Cholesterol and Span 60 
were purchased from Loba Chemie, Mumbai. Dicetyl Phosphate (DCP) was 
procured from Sigma-aldrich Pvt. Ltd. Mumbai, India. Dialysis memberane, 
12000-14000 molecular weight cut off was obtained from Himedia Laboratories 
Pvt Ltd India. all other reagents used were of analytical grade. 
2.2 Method of preparation of moxifloxacin hydrochloride niosomes 
Non-ionic surfactant vesicles containing Moxifloxacin hydrochloride were 




surfactant (span 60), Cholesterol, were accurately measured into a long 
necked quick fit round bottom flask and dissolved in 10 ml of a chloroform /
mixture (1:1, v/v). To the above mixture, dicetyl phosphate (DCP) was added 
in different concentrations i.e. 2.5%, 5% & 7.5%. The organic solvents were 
slowly evaporated under pressure, using a rotary evaporated (Model RVO5-ST, 
Perfit Laboratories, Chandigarh, India) at 60°C such that a thin dry film of the 
components was formed on the inner wall of the rotating flask. The film was re 
dissolved in 10ml of phosphate buffer saline (pH 7.4) solution containing 10 
mg drug was added. The mixture was sonicated for 2 min using ultra sonicator. 
The resultant opalescent dispersion was rotary evaporated to disrupt the gel 
formed immediately. Following addition of 10 ml phosphate buffered saline 
(pH 7.4); rotary evaporation was continued for additional 15 min duration to 
ensure the removal of residual organic solvents. The niosomal suspension was 











MN1 10 150 150 2.5
MN2 10 175 150 2.5
MN3 10 200 150 2.5
MN4 10 150 150 5.0
MN5 10 175 150 5.0
MN6 10 200 150 5.0
MN7 10 150 150 7.5
MN8 10 175 150 7.5
MN9 10 200 150 7.5










2.3 Evaluation parameters for moxifloxacin hydrochloride niosomes
2.3.1 Determination of pH
The ophthalmic formulations should have a pH 6.6-9.0 to avoid irritation. 
pH of the niosomal formulations were determined using pH meter (Digital 
Systronics, Mumbai, India).
2.3.2 Determination of moxifloxacin hydrochloride entrapment efficiency 
(%EE)
The portion of the encapsulated moxifloxacin hydrochloride was obtained by 
ultra-centrifugation 1ml of the niosomal suspension at 18000 rpm for 1hour using 
a cooling centrifuge at 4°C (ReMI, India). The supernatant was removed and the 
formed niosomal pellets were re-suspended in phosphate buffer saline (PBS) 
pH 7.4 to ensure the complete removal of all free moxifloxacin hydrochloride. 
The supernatant (free moxifloxacin hydrochloride) was collected and measured 
using uV spectrophotometer (Sytronics, Mumbai, India) at 287 nm using PBS 
pH 7.4 as blank. The concentration of entrapped moxifloxacin hydrochloride was 
determined spectrophotometerically after the lysis of the niosomal pellets with 
ethanol at 287nm, ethanol containing surfactant and cholesterol in the same ratio 
as in the niosomal formulations was used as a blank. The entrapped moxifloxacin 
hydrochloride concentration was expressed as percentage entrapment efficiency 
which can be defined as the percent fraction of the total input drug encapsulated in 
the surfactant bilayers and/or aqueous compartments in the niosomes (Chengjiu 
et al. 1999). It was calculated using the following equation:
entrapment efficiency (%ee
amount of Moxifloxecin entrapp
)=
ed
Totalamount of Moxifloxacin incorporsted
×100
2.3.3 Particle size and zeta potential 
Niosomal vesicle sizes of the prepared formulae were determined by light 
scattering based on laser diffraction using Malvern Mastersizer (Malvern 
Instrument Ltd., worcestershire, uK) (Junyaprasert et al., 2008). The 
measurements were performed using a 45mm focus objective and a beam length 
of 2.4mm. The samples diluted suitably by filtered water (0.5 micrometer filter- 
Himedia) were placed in the cuvettes and the procedure was carried out at 90° 
angle and temperature 25°C to determine the size of the particles in the range 
of 0.6nm to 3 microns. The zeta potential was determined using combination 
of laser Doppler velocimetry and phase analysis light scattering by Zetasizer 
Nano ZS-90 (Malvern Instruments Ltd.; uK). The diluted niosome dispersions 
were located in zeta meter cell for determination of electrophoretic mobility 




2.4 In vitro drug release study 
In vitro drug release studies of moxifloxacin from niosomes were carried out 
using membrane diffusion technique. In vitro diffusion cell was made using 
dialysis membrane as a semi permeable membrane. The diffusion cell consists 
of a test tube with both ends open. One end of the test tube was closed using 
presoaked dialysis membrane and the other end was open to introduce the 
niosomes formulation. an accurately measured amount of moxifloxacin 
niosomes formulation equivalent to 2 mg was suspended in 1ml PBS (pH 7.4) and 
then transferred it to test tube, having a diameter of 2.5cm that was covered with 
a dialysis membrane (12000-14000 molecular weight cut off). The test tube was 
suspended in the dissolution flask of a uSP dissolution apparatus containing 75 
ml PBS pH 7.4. The temperature of the solution was maintained at 37±0.5 °C 
and the glass tube was allowed to rotate at a constant speed (50 rpm). aliquots 
of the medium was withdrawn every hour and replaced with fresh PBS (pH 
7.4). The samples were analyzed using uV/Visible spectrophotometer (au-
2701 Systronics, Mumbai, India) at 287 nm (abdel-Mottaleb et al., 2011)
2.5 Kinetic analysis of release data
To study the release kinetics, the data obtained from in vitro drug release studies 
were plotted in various kinetic models as follows (Srinivas et al., 2010)

















Hixson-Crowell cube root law: Cube root of initial concentration minus iv. 


















 stand for the initial amount of drug, amount of drug 
release and kinetic release constant, respectively. M
t
/M∞ indicates the fractional 
drug release and “n” is the diffusional exponent which gives the mechanism of 
drug release dependent on the shape of matrix dosage form.
2.6 Transmission electron microscopy (TEM)
The morphology of the vesicles was examined by tramsmission electron 
microscopy (TeM). a drop of niosomal dispersion was diluted 10 times and 










removed by filter paper. a drop of 2% phosphotungstic acid solution was 
stratified to stain the vesicles; excess was removed by a tip of filter paper and 
left to air dry. The grid was observed by transmission electron microscopy 
(Hitachi, H-7500) and by using imaging viewer software the images were 
analyzed and captured (Muzzalupo et al., 2008).
2.7 Physical stability 
Niosomal formulations were sealed into 10 ml vials and stored at refrigerator 
temperature (4°C) and at room temperature (25°C) for three months. The 
stability of the niosomal formulations were measured by the extent of to which 
encapsulated moxifloxacin was retained. This can be done by the determination 
of percent entrapment (%ee) as mentioned before, taking the initial %ee 
values as 100% (Shahiwala et al., 2002).
2.8 Ocular irritancy of moxifloxacin hydrochloride niosomes 
a simple in vivo qualitative study was derived from modified Draize test for 
ocular irritation, without any scoring was performed to test the irritancy of 
Span type of surfactant used. The standard procedure involved the instillation 
of 0.1 ml of liquid (niosomal formulations) into the conjunctival sac of one 
eye and then gently holding the eye closed for one second. The untreated eye 
served as control. Both eyes were visually evaluated at 1, 6, 12, 24 48 and 72 
hours after instillation.
3. RESULTS AND DISCUSSION
3.1 pH
pH is most important parameter especially in case of ophthalmic formulations. 
as the pH of the tear fluid is 7.4. Variation in the pH causes irritation in the 
eye. The pH of all the formulations was found in the range of 7.32 to 7.44. The 
detailed values are given in Table 2.
3.2 Entrapment efficiency 
The entrapment efficiency was determined after separation of the un-
entrapped drug by ultracentrifugation method. The entrapment efficiencies 
of all niosomal formulations are reported in Table 2. The encapsulation 
efficiency of moxifloxacin hydrochloride in niosomes is found to be 




time the concentration of DCP also plays a vital role in determining the 
entrapment efficiency. DCP, being a charged molecule is often used to 
prevent niosomes aggregation and increase the stability of niosomes 
dispersions. The results reviled that, the formulation containing maximum 
concentration of DCP increased entrapment of moxifloxacin in formulation. 
This may be due to fact that cholesterol in the presence of DCP was more 
efficiently able to stabilize the structure of niosomal membrane in molar 
ratio of (1:1) (span60- cholesterol). a direct proportionality was observed 
between the concentration of DCP and the entrapment efficiency (when the 
molar concentration of cholesterol and span 60 was constant) when used 
in concentrations between 2.5 to 7.5%. On the other hand the increasing 












MN 1 43.12±0.56 3651 ± 36 -15.1 7.34
MN 2 41.91±0.56 3297 ± 64 -14.8 7.38
MN 3 39.22±0.60 2305 ± 76 -14.9 7.41
MN 4 46.23±0.85 3792 ± 55 -22.3 7.38
MN 5 42.41±0.51 3402 ± 47 -21.6 7.39
MN 6 40.08±0.36 2669 ± 83 -22.5 7.40
MN 7 48.45±0.44 3961 ± 29 -30.3 7.32
MN 8 45.68±0.75 3580 ± 61 -29.0 7.40
MN 9 41.29±1.05 3091 ± 27 -29.83 7.41










Surface Response graph of entrapment efficiency of Moxifloxacin 
Hydrochloride niosomes is given in Figure 1. The small ratio or quantity 
of DCP i.e. 2.5% led to decrease in percentage entrapment efficiency 
of moxifloxacin. So it is clear that the higher quantity of DCP with in a 
composition of cholesterol and span 60 (1:1) molar ratio is most beneficial 
for the highest entrapment of moxifloxacin as per result i.e.48.45 ± 0.75% 
compared to the other formulation.
The Table 2 also showed that the lowest entrapment of moxifloxacin was 
obtained due to small amount of DCP i.e. 2.5% as compared to formulation 
containing MN8 i.e. 7.5%. 
3.3 Particle size & Zeta potential
The particle size was determined from the graph obtained from dynamic light 
scattering method. The graph was obtained between particle diameter and 
percentage intensity. It was observed that increasing the concentration of DCP 
increases the particle size when used in the concentration range between 2.5 to 
7.5%. This effect may be observed because the charge imparted by DCP causing 
the streaching of bilayer. On the other hand with increase in concentration 
of span 60 there was a marked decrease in the vesicle diameter. The highest 





vesicle diameter was obtained for formulation MN7 with a diameter of 3961 
± 29 nm shown in Figure 2 and formulation MN3 was characterized with the 
lowest particle size of 2305 ± 76nm. The surface response graph representing 
the effects of concentration of DCP and concentration of span 60 over the 
particle size of niosomes is given in Figure 2 and the particles size of different 
formulation is given in Table 2. Data in Table 2 & Figure 2 &3 show the Zeta 
potential of all the niosomes. Result showed that the zeta potential depends 
on the movement of particles (electrophoretic velocities). Result showed that 
niosomal formulation MN7 showed highest zeta potential -30.3 mV. The 
formulation MN2 showed lowest zeta potential. The value of zeta potential 
varied from -14.8 mV to -30.3mV. The presence of DCP incorporate negative 











r2 r2 r2 r2 r2 n
MN1 0 .8768 0.848 0.992 0.917 0.995 0.497
MN2 0.833 0.871 0.973 0.905 0.963 0.440
MN3 0.741 0.343 0.985 0.825 0.986 0.189
MN4 0.932 0.482 0.958 0.934 0.939 0.475
MN5 0.796 0.847 0.932 0.881 0.898 0.407
MN6 0.7014 0.847 0.956 0.808 0.957 0.303
MN7 0.895 0.823 0.957 0.879 0.946 0.500
MN8 0.925 0.895 0.9694 0.927 0.956 0.491
MN9 0.801 0.871 0.9646 0.892 0.934 0.378









































































































































































































































































































































Figure 2: Surface Response graph representing the effect of different 
concentration of DCP and Span 60 on particle size.
Figure 3: Size Distribution Curve of MN7 (3651 nm).
niosomal suspension over the cornea due to the electrostatic attraction between 










Time(hrs) Rabbit 1 Rabbit 2 Rabbit 3 Average
1 2 1 2 1.67
6 2 1 1 1.33
12 1 0 1 0.67
24 1 0 0 0.33
48 0 0 0 0
72 0 0 0 0
Table 5: Ocular irritation study of optimized niosomes formulations.
Figure 4: Zeta potential of Moxifloxacin Hydrochloride niosomes.
3.4 In vitro release studies
The in vitro drug release studies were carried out for all niosomal formulations 
using membrane diffusion technique (12000-14000 mol. wt. cut off). The in 
vitro release of moxifloxacin from niosomal formulations by different molar 
ratio using different concentration of cholesterol, span 60 and DCP. The 
formulation containing maximum concentration of DCP i.e. 7.5% w/w provide 
retarded release, due to its stabilization action the niosomal formulations 
became less permeable. It is also concluded that the equal molar ratio of span 




Figure 5: Cumulative release (%) profile of Moxifloxacin Hydrochloride 
niosomes (MM1-MN4).
Figure 6: Cumulative release (%) profile of Moxifloxacin Hydrochloride 
niosomes (MN5-MN9).
niosomal formulation as compared to other prepared formulations. The result 
also showed that the combination of span 60 and cholesterol (1:1) proportions 
gave better sustained action of drug through niosomal formulations. The 
formulation MN3 (span 60: cholesterol) molar ratio produce faster release of 
drug i.e. 77.98% after 12 hours, concluded less sustained action. Niosomal 
formulations showed slower release rate than Moxifloxacin Hydrochloride 
marketed formulation. It also needed to note that in vitro release from niosomal 
formulation after 12 hours can be followed by decreasing order:MN3 > MN6 > 










3.5 Release kinetics study
The drug release data obtained after in vitro release study was further analysed 
by various kinetic models plotted i.e. zero order, first order, Higuchi equation 
and Hixon Crowell cube root law. The regressed values of release profiles 
and the ‘n’ value of Korsmeyer Peppas model is given in table 3. all the 
formulations have shown to follow the higuchi kinetics as its coefficient of 
determinations (r2) is much closer to one in most of the cases. The batches 
where the coefficient of determination has a value closer to 1 for Korsmeyer 
Peppas model have shown ‘n’ value either between 0.43 – 0.87 or their ‘n’ 
value is much lower than 0.43 so it can be visualized that Higuchi kinetics 
can be applied to the formulations with better accuracy and the formulations 
release the drug through non-fickian release kinetics.
3.6 Physical stability study
Physical stability study of optimized niosomes formulation MN7 were carried 
out to investigate the leaching of drug from niosomes by storing formulation 
under two different conditions i.e. in refrigerator (4-8 0C) and in room 
temperature (250C) for one month. The samples were withdrawn after 7th, 15th, 
30th day, and analysed for entrapment efficiency. The results of stability studies 
are given in table 4 and in figure 7. The initial entrapment efficiency at the start 




of stability study was 48.45%. at cool temperature the formulation was stable 
over a period of 30 days and the percentage leaching of the drug in comparison 
to the initial entrapment was 4.26% in one month. The entrapment efficiency 
at refrigerator condition was found to be 46.39 ± 0.49% and at room condition 
was found to be 45.11 ± 0.51% at the end of one month stability period. at 
room temperature the percentage leaching of the drug in comparison of the 
initial entrapment was 6.88% in one month.
3.7 Transmission electron microscopy (TEM)
The prepared niosomal solution was a homogeneous dispersion and after 
maturation of 24 hours was studied under the microscope for morphological 
evaluation. The vesicles were uniform, spherical in shape with traces of 
aggregation. The formulations prepared with inclusion of DCP were found to 
be free from aggregation.
3.8 Ocular irritancy of niosomes
The results of the ocular irritation studies indicates that formulation MN7 
having no redness, inflammation or increased tear production. excellent 
ocular tolerance was noted. The results of the ocular irritation studies indicate 
that optimized formulation are non- irritant and well tolerated. The values 
of ocular irritancy are given in table 5. The ocular suspension showed mild 
irritation during the first six hours but irritation was reduced within 24 hours 
of application and no irritation was observed at 48 and 72 hours interval in any 
of the rabbits.
4. CONCLUSIONS
The present study conclusively supported niosomes to be an advantageous 
drug delivery system with high degree of entrapment and sustained release of 
the drug over extended period of time. It also suggests that the higher quantity 
of DCP with in a composition of cholesterol and span 60 (1:1) molar ratios is 
most beneficial for the highest entrapment of moxifloxacin. The careful control 
of all the above factors allow the production of a dosage form with sustained 
release capable of combating the side effects and also reducing the dosing 
frequency with the greater patient compliance.
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